Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Jonathan W. Goldman et al.
LANCET ONCOLOGY (2021)
Small-cell lung cancer
Charles M. Rudin et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Reframing recalcitrance for small-cell lung cancer
F. H. Blackhall
ANNALS OF ONCOLOGY (2021)
Clinical characteristics of long-term survivors (LTS) in small cell lung cancer (SCLC) patients (p) with extended disease (ED)
A. Plaja et al.
ANNALS OF ONCOLOGY (2021)
VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
S. V. Liu et al.
ANNALS OF ONCOLOGY (2021)
Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment
Andrea Bianco et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2021)
Prognostic Value of Ki-67 Expression in Advanced Lung Squamous Cell Carcinoma Patients Treated with Chemotherapy
Diming Wang et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Neal E. Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Targeted Therapies and Biomarkers in Small Cell Lung Cancer
Hirokazu Taniguchi et al.
FRONTIERS IN ONCOLOGY (2020)
Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
J. W. Goldman et al.
ANNALS OF ONCOLOGY (2020)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer (vol 33, pg 853, 2018)
Matthew D. Hellmann et al.
CANCER CELL (2019)
Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment
Xiaoliang Zhao et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer
Prasuna Muppa et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Immune Cell Infiltration Is a Strong Prognostic Indicator in Surgical Resection of SCLC
Ningning Zhou et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Characteristics of Exceptional Long Term Survivors in Extensive Stage Small Cell Lung Cancer
Kunlatida Maneenil et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
xCell: digitally portraying the tissue cellular heterogeneity landscape
Dvir Aran et al.
GENOME BIOLOGY (2017)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Software for Computing and Annotating Genomic Ranges
Michael Lawrence et al.
PLOS COMPUTATIONAL BIOLOGY (2013)
Fast and SNP-tolerant detection of complex variants and splicing in short reads
Thomas D. Wu et al.
BIOINFORMATICS (2010)
Prognostic factors of small cell lung cancer
G Buccheri et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
Control of effector CD8+ T cell function by the transcription factor Eomesodermin
EL Pearce et al.
SCIENCE (2003)
Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice
BJ Johnson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up
RM Bremnes et al.
LUNG CANCER (2003)
A novel transcription factor, T-bet, directs Th1 lineage commitment
SJ Szabo et al.
CELL (2000)
Share Paper
